WO2019051122A3 - CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS - Google Patents

CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS Download PDF

Info

Publication number
WO2019051122A3
WO2019051122A3 PCT/US2018/049798 US2018049798W WO2019051122A3 WO 2019051122 A3 WO2019051122 A3 WO 2019051122A3 US 2018049798 W US2018049798 W US 2018049798W WO 2019051122 A3 WO2019051122 A3 WO 2019051122A3
Authority
WO
WIPO (PCT)
Prior art keywords
regions
activated binding
conditionally activated
binding moieties
moieties containing
Prior art date
Application number
PCT/US2018/049798
Other languages
French (fr)
Other versions
WO2019051122A2 (en
Inventor
Robert B. Dubridge
Anand PANCHAL
Original Assignee
Maverick Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverick Therapeutics, Inc. filed Critical Maverick Therapeutics, Inc.
Priority to CN201880072457.XA priority Critical patent/CN111315773A/en
Priority to JP2020513722A priority patent/JP2020534811A/en
Priority to EP18782834.8A priority patent/EP3679068A2/en
Publication of WO2019051122A2 publication Critical patent/WO2019051122A2/en
Publication of WO2019051122A3 publication Critical patent/WO2019051122A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided herein are compositions of conditionally activated binding proteins containing Fc regions, and methods for coexpressing and purifying such conditionally activated binding proteins. Also provided are methods of treating cancer by administering the conditionally activated binding proteins to a patient.
PCT/US2018/049798 2017-09-08 2018-09-06 CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS WO2019051122A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201880072457.XA CN111315773A (en) 2017-09-08 2018-09-06 Conditionally active binding moieties comprising an Fc region
JP2020513722A JP2020534811A (en) 2017-09-08 2018-09-06 Conditionally activated binding moiety containing the Fc region
EP18782834.8A EP3679068A2 (en) 2017-09-08 2018-09-06 CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762555943P 2017-09-08 2017-09-08
US201762555999P 2017-09-08 2017-09-08
US62/555,943 2017-09-08
US62/555,999 2017-09-08

Publications (2)

Publication Number Publication Date
WO2019051122A2 WO2019051122A2 (en) 2019-03-14
WO2019051122A3 true WO2019051122A3 (en) 2019-04-11

Family

ID=63788012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/049798 WO2019051122A2 (en) 2017-09-08 2018-09-06 CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS

Country Status (4)

Country Link
EP (1) EP3679068A2 (en)
JP (1) JP2020534811A (en)
CN (1) CN111315773A (en)
WO (1) WO2019051122A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200047687A (en) 2017-09-08 2020-05-07 매버릭 테라퓨틱스, 인크. Constrained conditionally activated binding protein
US20210309756A1 (en) 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
CN114173876A (en) 2019-03-05 2022-03-11 武田药品工业有限公司 Conditionally active binding proteins containing Fc regions and moieties targeting tumor antigens
WO2020181140A1 (en) * 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
SG11202112541RA (en) * 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
EP4058471A1 (en) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
WO2022051647A2 (en) * 2020-09-04 2022-03-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding protein constructs with human serum albumin domains
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
EP4395812A1 (en) 2021-08-31 2024-07-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
AU2022396272A1 (en) 2021-11-24 2024-06-06 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
CA3241407A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
CA3241395A1 (en) 2021-12-17 2023-06-22 Barbel SCHROFELBAUER Antibodies and uses thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2016046778A2 (en) * 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
WO2016179285A1 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ATE237694T1 (en) 1991-08-20 2003-05-15 Us Gov Health & Human Serv ADENOVIRUS-MEDIATED GENE TRANSFER INTO THE GASTROINTESTINAL TRACT
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
JP3532566B2 (en) 1993-06-24 2004-05-31 エル． グラハム，フランク Adenovirus vectors for gene therapy
ATE314482T1 (en) 1993-10-25 2006-01-15 Canji Inc RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE60022369T2 (en) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy PROCESS FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE10231109A1 (en) 2002-07-10 2004-01-22 Daimlerchrysler Ag exhaust turbine
MX2015014608A (en) * 2013-04-19 2016-03-03 Covagen Ag Novel bispecific binding molecules with antitumoral activity.
CN106632681B (en) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 Anti- EGFR and AntiCD3 McAb bispecific antibody and its application

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2016046778A2 (en) * 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
WO2016179285A1 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAD MAY ET AL: "Advances in bispecific biotherapeutics for the treatment of cancer", BIOCHEMICAL PHARMACOLOGY, vol. 84, no. 9, 1 November 2012 (2012-11-01), pages 1105 - 1112, XP055071310, ISSN: 0006-2952, DOI: 10.1016/j.bcp.2012.07.011 *
FRANKEL STANLEY R ET AL: "Targeting T cells to tumor cells using bispecific antibodies", ENGINEERED PROTEIN SCAFFOLDS AS NEXT-GENERATION ANTIBODY THERAPEUTICS,, vol. 17, no. 3, 1 June 2013 (2013-06-01), pages 385 - 392, XP002787546, ISSN: 1879-0402 *

Also Published As

Publication number Publication date
CN111315773A (en) 2020-06-19
WO2019051122A2 (en) 2019-03-14
JP2020534811A (en) 2020-12-03
EP3679068A2 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
WO2019051122A3 (en) CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
MX2020013881A (en) Bcl-xl inhibitory compounds and antibody drug conjugates including the same.
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2019009468A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer.
WO2016100261A3 (en) Method of treating cancer with cgamp or cgasmp
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2017007641A (en) Antibody drug conjugates with cell permeable bcl-xl inhibitors.
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
SG10201900315SA (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
MX2019009566A (en) Proteins binding bcma, nkg2d and cd16.
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP4233910A3 (en) Methods of treatment of cholestatic diseases
EP4011871A3 (en) Processes for preparing oxathiazin-like compounds
MX2018015172A (en) Methods of treating pancreatic cancer.
WO2014151369A3 (en) Stabilized ezh2 peptides
EP4342473A3 (en) Compounds useful in hiv therapy
EP4414035A3 (en) Combined preparations for the treatment of cancer
MX2019009943A (en) Proteins binding gd2, nkg2d and cd16.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
AU2018321118A1 (en) Boronic acid derivatives
MX2017010341A (en) Cancer therapy with a parvovirus combined with bevacizumab.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18782834

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020513722

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018782834

Country of ref document: EP

Effective date: 20200408